Overview
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.
Background
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.
Indication
Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.
Associated Conditions
- Acromegaly
- Diarrhea
- Metastatic Carcinoid Tumors
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2018/05/30 | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | ||
2018/05/09 | Early Phase 1 | Completed | |||
2017/09/21 | Phase 4 | Completed | |||
2017/08/17 | Phase 3 | UNKNOWN | |||
2017/06/07 | Phase 2 | Terminated | |||
2017/05/17 | N/A | Recruiting | Ginkgo Leaf Center for Rare Disorders | ||
2017/02/23 | Not Applicable | Completed | |||
2017/01/25 | Phase 1 | Completed | Dauntless Pharmaceuticals | ||
2016/12/22 | Phase 3 | Completed | |||
2016/11/30 | N/A | UNKNOWN |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-689 | INTRAVENOUS, SUBCUTANEOUS | 500 ug in 1 mL | 1/10/2024 | |
Amryt Pharmaceuticals Designated Activity Company | 69880-120 | ORAL | 20 mg in 1 1 | 9/15/2023 | |
Gland Pharma Limited | 68083-516 | SUBCUTANEOUS, INTRAVENOUS | 1000 ug in 1 mL | 12/20/2023 | |
USV North America Inc. | 76135-009 | INTRAVENOUS, SUBCUTANEOUS | 50 ug in 1 mL | 2/7/2013 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Octreotide Acetate Injection | 国药准字H20133091 | 化学药品 | 注射剂 | 9/20/2022 | |
Octreotide Acetate Injection | 国药准字HJ20140908 | 化学药品 | 注射剂 | 9/30/2024 | |
Octreotide Acetate Microspheres for Injection | 国药准字H20233996 | 化学药品 | 注射剂 | 8/1/2023 | |
Octreotide Acetate Microspheres for Injection | 国药准字H20233997 | 化学药品 | 注射剂 | 8/1/2023 | |
Octreotide Acetate Microspheres for Injection | 国药准字HJ20171261 | 化学药品 | 注射剂 | 8/18/2022 | |
Octreotide Acetate Microspheres for Injection | 国药准字HJ20171262 | 化学药品 | 注射剂 | 8/18/2022 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |